Fluticasone furoate will reach the US OTC market as Flonase Sensimist Allergy Relief following FDA's recent FDA approval of GlaxoSmithKline PLC's supplemental new drug application to market its previously Rx product Veramyst (fluticasone furoate/0.0275mg metered spray) over-the counter.
Flonase Sensimist is planned for a 2017 first-quarter launch in the US and Puerto Rico by GlaxoSmithKline Consumer Healthcare LP, theGlaxo and Novartis AG joint venture marketing the firms' OTC drugs and nutritional products